Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders

被引：13

作者：

Fragoso, Yara Dadalti ^{[1
]}

Adoni, Tarso ^{[2
]}

Alves-Leon, Soniza Vieira ^{[3
]}

Apostolos-Pereira, Samira Luisa ^{[4
]}

Barreira, Amilton Antunes ^{[5
]}

Bidin Brooks, Joseph Bruno ^{[1
]}

Claudino, Rinaldo ^{[6
]}

Correa, Eber Castro ^{[7
]}

Brito Ferreira, Maria Lucia ^{[8
]}

Finkelsztejn, Alessandro ^{[9
]}

Finkelsztejn, Juliana ^{[9
]}

da Gama, Paulo Diniz ^{[10
]}

Magno Goncalves, Marcus Vinicius ^{[11
]}

Guerreiro, Carlos Tostes ^{[5
]}

da Cunha Matta, Andre Palma ^{[12
]}

Marques, Vanessa Daccach ^{[5
]}

Morales, Rogerio Rizo ^{[13
]}

Koncke Parolin, Monica Fiuza ^{[14
]}

Ribeiro, Marlise de Castro ^{[15
]}

Gonsalves Jube Ribeiro, Taysa Alexandrino ^{[16
]}

Ruocco, Heloisa Helena ^{[17
]}

Sato, Henry ^{[18
]}

Scherpenhuijzen, Simone ^{[3
]}

Siquineli, Fabio ^{[19
]}

de Carvalho Sousa, Nise Alessandra ^{[20
]}

Varela, Daniel Lima ^{[21
]}

Tauil, Carlos Bernardo ^{[22
]}

Winckler, Thereza Cristina ^{[23
]}

机构：

[1] Univ Metropolitana Santos, Dept Neurol, Santos, SP, Brazil

[2] Hosp Sirio Libanes, Dept Neurol, Sao Paulo, SP, Brazil

[3] Univ Fed Estado Rio de Janeiro, Dept Neurol, Rio De Janeiro, RJ, Brazil

[4] Univ Sao Paulo, Dept Neurol, Sao Paulo, SP, Brazil

[5] Univ Sao Paulo Campus Ribeirao Preto, Dept Neurol, Ribeirao Preto, SP, Brazil

[6] Univ Fed Santa Catarina, Dept Neurol, Florianopolis, SC, Brazil

[7] CLINEN, Dept Neurol, Brasilia, DE, Brazil

[8] Hosp Restauracao, Dept Neurol, Recife, PE, Brazil

[9] Hosp Clin Porto Alegre, Dept Neurol, Porto Alegre, RS, Brazil

[10] Pontificia Univ Catolica Campus Sorocaba, Dept Neurol, Sorocaba, SP, Brazil

[11] Ctr Hosp Unimed, Dept Neurol, Joinville, SC, Brazil

[12] Univ Fed Fluminense, Dept Neurol, Niteroi, RJ, Brazil

[13] Univ Fed Uberlandia, Dept Neurol, Uberlandia, MG, Brazil

[14] Neurol Clin, Dept Neurol, Curitiba, PR, Brazil

[15] Univ Fed Ciencias Saude Porto Alegre, Dept Neurol, Porto Alegre, RS, Brazil

[16] Univ Fed Goias, Dept Neurol, Goiania, Go, Brazil

[17] Fac Med Jundiai, Dept Neurol, Jundiai, SP, Brazil

[18] Neurol Inst Curitiba, Dept Neurol, Curitiba, PR, Brazil

[19] Univ Reg Blumenau, Dept Neurol, Blumenau, SC, Brazil

[20] Hosp Univ Getulio Vargas, Dept Neurol, Manaus, Amazonas, Brazil

[21] Serv Neurol & Neurocirurgia Passo Fundo, Dept Neurol, Passo Fundo, RS, Brazil

[22] Hosp Base Dist Fed, Dept Neurol, Brasilia, DE, Brazil

[23] Univ Posit, Dept Neurol, Curitiba, PR, Brazil

来源：

NEUROREHABILITATION | 2016年 / 39卷 / 02期

关键词：

Multiple sclerosis; gait; walking; fampridine; PROLONGED-RELEASE FAMPRIDINE; 4-AMINOPYRIDINE; WALKING; MS;

D O I：

10.3233/NRE-161361

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

BACKGROUND: Fampridine is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to ameliorate conduction in demyelinated axons, thereby leading to improved gait in patients with multiple sclerosis (MS). OBJECTIVE: To assess the "real-life" efficacy and safety of fampridine prescribed for gait disorders in MS. This was an observational and prospective study carried out at MS Units participating in the Brazilian Multiple Sclerosis Study Group. METHODS: Patients with MS and gait disorders were prescribed fampridine (10 mg twice a day), irrespectively of the degree of disability determined by MS. Neurological disability determined by MS was assessed with the expanded disability scale score (EDSS). Outcomes for efficacy and safety of the drug were evaluated by the 25 foot-walk test and by the adverse events of fampridine. RESULTS: The time taken to walk 25 feet decreased by 20% or more in 62 patients (70%). Twenty-five patients were considered to be non-responders to this treatment. Improvement in walking speed was independent of improvement of disability. Mild or moderate adverse events were reported in 8% of patients. CONCLUSION: Fampridine is an efficient and safe therapeutic option for patients with MS and gait disorders.

引用

页码：301 / 304

页数：4

共 50 条

[31] Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience
Martinez-Poles, Javier
Nedkova-Hristova, Velina
Bernardo Escribano-Paredes, Jose
Garcia-Madrona, Sebastian
Natera-Villalba, Elena
Estevez-Fraga, Carlos
Lopez-Sendon Moreno, Jose Luis
Aviles-Olmos, Iciar
Sanchez Diaz, Gema
Martinez Castrillo, Juan Carlos
Alonso-Canovas, Araceli
[J]. TOXINS, 2018, 10 (06):
[32] Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
Rodriguez-Leal, Francisco Alejandro
Haase, Rocco
Akguen, Katja
Eisele, Judith
Proschmann, Undine
Schultheiss, Thorsten
Kern, Raimar
Ziemssen, Tjalf
[J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2019, 10 : 1 - 11
[33] Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis
Sahar Ghorbanpour
Sarvenaz Rahimibarghani
Setareh Rohani
Mohsen Rastkar
Mahsa Ghajarzadeh
[J]. Neurological Sciences, 2023, 44 : 3059 - 3069
[34] The impact of fampridine treatment on fatigue, quality of life and mood in patients with multiple sclerosis
Barros, A.
Sequeira, J.
Vaz, S.
Morgado, J.
Bras, P.
Melancia, D.
Fernandes, A.
Sousa, A.
Dias, S.
Capela, C.
Pedrosa, R.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 688 - 688
[35] Initial real-life experience with ocrelizumab in patients with relapsing-remitting and primary progressive multiple sclerosis in Salzburg, Austria
Feige, J.
Moser, T.
Nagy, Z.
Otto, F.
Wipfler, P.
Trinka, E.
Sellner, J.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 489 - 489
[36] Real-Life Experience with Perampanel in 36 Patients
Tagliafico, L.
Di Biasio, F.
Fancellu, R.
Serrati, C.
Ferrari, A.
[J]. EPILEPSIA, 2018, 59 : S271 - S272
[37] Real-life experience of guselkumab in patients with psoriasis
Snast, Igor
Sherman, Shany
Holzman, Roie
Hodak, Emmilia
Pavlovsky, Lev
[J]. DERMATOLOGIC THERAPY, 2020, 33 (06)
[38] Real-life data from efficacy of fingolimod treatment in multiple sclerosis patients in Turkey
Terzi, M.
Kurtuncu, M.
Eraksoy, M.
Karabudak, R.
Tuncer, A.
Altunrende, B.
Akcali, A.
Boz, C.
Sevim, S.
Nur, Y.
Tamam, Y.
Bitnel, M.
Turan, O. F.
Soysal, A.
Ozerden, M.
Terzi, Y.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 310 - 310
[39] Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis
Ghorbanpour, Sahar
Rahimibarghani, Sarvenaz
Rohani, Setareh
Rastkar, Mohsen
Ghajarzadeh, Mahsa
[J]. NEUROLOGICAL SCIENCES, 2023, 44 (09) : 3059 - 3069
[40] Gait quality and function after fampridine treatment in patients with multiple sclerosis - A prospective cohort study
Thorning, Maria
Nielsen, Helle Hvilsted
Frich, Lars Henrik
Jensen, Henrik Boye
Lambertsen, Kate Lykke
Holsgaard-Larsen, Anders
[J]. CLINICAL BIOMECHANICS, 2022, 100

← 1 2 3 4 5 →